What's in Haaglanden Medical Centre's pipeline?

Haaglanden Medical Centre has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Haaglanden Medical Centre's portfolio?

Top competitors by shared drug class: Aldeyra Therapeutics, Inc., Alexion Pharmaceuticals, Inc., BioCryst Pharmaceuticals, CSL Behring, InflaRx GmbH.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/haaglanden-medical-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Haaglanden Medical Centre — Portfolio Competitive Intelligence Brief

Haaglanden Medical Centre pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aldeyra Therapeutics, Inc. · 1 shared drug class
Alexion Pharmaceuticals, Inc. · 1 shared drug class
BioCryst Pharmaceuticals · 1 shared drug class
CSL Behring · 1 shared drug class
InflaRx GmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Haaglanden Medical Centre:

Cite this brief

Drug Landscape (2026). Haaglanden Medical Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/haaglanden-medical-centre. Accessed 2026-05-16.